

15th MADRID
on **Lung** CONGRESS
CANCER
23&24
November 2023

#15CongressGeCP

REGISTRIES AND DATABASE

JOAQUÍN MOSQUERA MARTÍNEZ

Hospital Universitario de A Coruña



DISCLOSURES

Speaker: Astrazeneca, BMS, Leo Pharma, Roche, Rovi, Takeda.

Travel expenses: Astrazeneca, BMS, Leo Pharma, Lilly, MSD, Roche, Rovi.



GECP




Estudio observacional (No-EPA), multicéntrico, en pacientes con cáncer de pulmón y otros tumores torácicos para conocer la epidemiología descriptiva del cáncer de pulmón y otros tumores torácicos en España, así como datos clínicos, histológicos, diagnósticos, tratamientos recibidos y factores pronósticos.


CENTROS PARTICIPANTES



PACIENTES INCLUIDOS



*Datos de noviembre de 2023



*Datos de noviembre de 2023



004	HOSPITAL REG. MÁLAGA y H. VIRGEN VICTORIA	Dr. Manuel Cobo y Dr. JM Trigo	21/07/2016	3821
005	HOSPITAL PUERTA DE HIERRO	Dr. Mariano Provencio Pulla	21/07/2016	3682
013	HOSPITAL INSULAR DE GRAN CANARIA	Dr. Delvys Rodríguez Abreu	15/11/2016	2105
002	HOSPITAL GERMANS TRIAS I PUJOL	Dr. Enric Carcereny	22/12/2016	1724
051	HOSPITAL CLÍNICO UNIV. DE VALLADOLID	Dr. Rafael López Castro	24/11/2017	1328
015	HOSPITAL UNIVERSITARIO A CORUÑA	Dra. Rosario García Campelo	28/03/2017	1269
021	ICO-GIRONA	Dr. Joaquim Bosch Barrera	16/03/2017	1162
053	HOSPITAL VIRGEN DEL ROCIO	Dra. Reyes Bernabé	27/03/2017	1092
035	HOSPITAL UNIVERSITARIO Y POLITÉCNICO LA FE	Dr. Oscar Juan Vidal	02/02/2017	1079
007	HOSPITAL UNIV. FUNDACIÓN JIMÉNEZ DÍAZ	Dr. Manuel Dómine	15/11/2016	1022
028	COMPLEJO HOSPITALARIO DE JAÉN	Dra. Ana Laura Ortega Granados	22/11/2016	1008
001	HOSPITAL GENERAL DE ALICANTE	Dr. Bartomeu Massutí	13/02/2017	994
012	CONSORCIO HOSP. PROVINCIAL DE CASTELLÓN	Dr. Alfredo Sánchez	14/11/2016	850
063	COMPLEJO ASISTENCIAL UNIV. DE SALAMANCA	Dr. Edel del Barco Morillo	26/10/2016	847
003	HOSPITAL GENERAL DE VALENCIA	Dr. Carlos Camps	11/11/2016	744
023	HOSPITAL GENERAL UNIVERSITARIO DE ELCHE	Dra. María Guirado Rísueño	04/08/2016	675
157	COMPLEJO HOSPITALARIO UNIV. DE VIGO	Dr. Joaquín Casal Rubio	04/10/2016	611
055	H. UNIV. NUESTRA SEÑORA DE LA CANDELARIA	Dra. Karla Medina	06/07/2017	610
029	HOSPITAL DE BASURTO	Dra. M ^a Ángeles Sala	02/02/2017	607
009	HOSPITAL CLÍNICO SAN CARLOS	Dr. JL. González Larriba	15/11/2016	583
072	HOSPITAL UNIVERSITARIO LUCUS AGUSTÍ	Dr. Sergio Vázquez	04/02/2020	469
074	HOSPITAL UNIVERSITARIO DR. NEGRÍN	Dr. David Aguiar	26/03/2018	456
097	HOSPITAL GENERAL LA MANCHA CENTRO	Dra. Sara Cerezo	10/03/2017	407
034	HOSPITAL UNIVERSITARIO DE CANARIAS	Dra. Juana Oramas	05/12/2017	395
094	COMPLEJO HOSPITALARIO DE NAVARRA	Dra. Idoia Morilla	20/04/2017	345
106	HOSPITAL UNIVERSITARIO DE FUENLABRADA	Dra. Beatriz Losada	11/01/2017	336
046	CONSORCI SANITARI DE TERRASSA	Dra. Remei Blanco	01/12/2016	326
030	HOSPITAL DE MATARÓ	Dra. Laura Puntí	12/01/2017	264
127	HOSPITAL DE JEREZ	Dra. M ^a Angeles Moreno	06/04/2021	226
113	HOSPITAL SAN PEDRO DE ALCÁNTARA	Dr. Rubén Alonso	16/09/2019	215
129	HOSPITAL SANTA MARIA NAI	Dra. Karmele Areses	23/12/2019	205
033	HOSPITAL VIRGEN DE LAS NIEVES	Dr. Javier Valdívila Bautista	16/05/2017	180
037	COMPLEJO ASISTENCIAL UNIV. DE LEÓN	Dra. Soledad Medina	16/10/2017	166
119	HOSPITAL DE CIUDAD REAL	Dr. José Carlos Villa	27/05/2019	152
084	HOSPITAL UNIV DE BADAJOZ	Dra. Marta González	24/02/2021	147
038	INSTITUTO VALENCIANO DE ONCOLOGÍA	Dr. Sergio Sandiego	10/07/2017	109
108	HOSPITAL SANT PAU I SANTA TECLA	Dra. Laia Capdevila	07/04/2017	106

043	HOSPITAL MORALES MESSEGUER	Dr. José Antonio Macías	13/10/2016	103
099	HOSPITAL LLUÍS ALCANYÍS	Dra. Julia Hidalgo	29/03/2017	100
042	HOSPITAL UNIVER. FUNDACIÓN ALCORCÓN	Dr. Xabier Mielgo Rubio	17/10/2016	100
078	HOSPITAL SAN CECILIO	Dra. Silvia Sequero	17/02/2021	91
064	COMPLEJO HOSPITALARIO UNIV. DE ALBACETE	Dra. Esther Noguero Martínez	07/12/2016	87
147	HOSPITAL INFANTA SOFÍA	Dra. María Sereno	27/09/2016	75
024	HOSPITAL SON ESPASES	Dr. Aitor Azkárate	04/08/2017	69
114	H. GENERAL UNIV. VIRGEN DE LA ARRIXACA	Dra. Juana Campillo Fuentes	18/05/2017	53
062	HOSPITAL SEVERO OCHOA	Dra. Ana López	04/05/2021	53
077	HOSPITAL DE SAGUNTO	Dra. Sara Blasco	27/07/2020	51
070	HOSPITAL UNIV. DE ARABA (TXAGORRITXU)	Dra. Mireia Martínez Kareaga	24/01/2017	48
036	HOSPITAL UNIVERSITARIO LA PAZ	Dr. Javier de Castro	11/10/2017	45
071	HOSPITAL UNIVERSITARIO DE DONOSTIA	Dr. Alfredo Paredes	15/02/2017	45
010	HOSPITAL DE LA SANTA CREU I SANT PAU	Dra. Margarita Majem	06/04/2017	39
190	UOMI-CLÍNICA TRES TORRES BARCELONA	Dr. Santiago Víterí	27/08/2021	39
066	CLÍNICA UNIVERSIDAD DE NAVARRA	Dr. Ignacio Gil Bazo	11/05/2017	33
083	HOSPITAL DE ELDA	Dra. Elísa Gálvez	12/07/2018	29
065	COMPLEJO HOSPITALARIO DE ZAMORA	Dra. de Portugal/ Dra. Díaz	15/02/2017	29
039	HOSPITAL VIRGEN DE LOS LIROS DE ALCOY	Dra. Milagros Franco	05/10/2016	27
025	HOSPITAL UNIVERSITARIO DE LA PRINCESA	Dr. José Miguel Sánchez Torres	20/01/2017	27
103	HOSPITAL PUERTO REAL	Dra. Petra Rosado	30/05/2018	26
058	HOSPITAL UNIVERSITARI SAN JOAN DE REUS	Dra. Cristina Martí Blanco	23/12/2016	25
045	HOSPITAL FUNDACIÓ ALTHAIA	Dra. Silvia Catot	12/08/2020	25
073	HOSPITAL VIRGEN DE LA MACARENA	Dra. Inmaculada Fernández	20/04/2021	24
069	HOSPITAL UNIVERSITARIO QUIRÓN MADRID	Dra. Belén Rubio Viqueira	30/01/2017	21
080	HOSPITAL UNIV DE LA RIBERA	Dra. Corina Escoín	22/07/2022	20
173	HOSPITAL CIMA SANITAS	Dr. Julio Ocaña	08/06/2020	19
146	HOSPITAL HM SANCHINARRO-C. CAMPAL	-	24/11/2017	12
027	HOSPITAL GREGORIO MARAÑÓN	Dr. Antonio Calles	04/03/2020	12
018	HOSPITAL ARNAU DE VILANOVA	Dr. José García	21/03/2018	10
180	HOSPITAL INFANTA LEONOR	Dra. Gloria M ^a Serrano	21/05/2020	10
031	HOSPITAL DR PESET	Dra. María Martín Ureste	16/06/2017	9
098	HOSPITAL VIRGEN DE LA LUZ	Dra. Soraya Simón	31/10/2017	8
060	HOSPITAL UNIV DE TOLEDO (V. SALUD)	Dra. Ruth Álvarez	15/01/2018	6
177	HM HOSPITAL NTRA SRA DE LA ESPERANZA	Dr. Manuel Fernández	21/11/2018	6
145	HOSPITAL INFANTA CRISTINA	Dra. Adriana Rosero	01/12/2017	5
125	HOSPITAL MARINA BAIXA	Dr. Henry Martín Oré	16/03/2021	4
191	HOSPITAL UNIV DE TARRAGONA. JOAN XXIII	Dra. Vanesa López	27/08/2021	4



154	HOSPITAL VERGE DE LA CINTA	Dra. Ángela Moreno	08/05/2020	3
159	HOSPITAL GENERAL UNIVER.SANTA LUCÍA	Dr. Salinas/Dr. Balsalobre	27/10/2016	2
128	HOSPITAL UNIVERSITARIO DE MÓSTOLES	Dra. Judit Rubio	06/03/2020	2
161	HOSPITAL QUIRON SALUD MÁLAGA	Dr. José Antonio Ortega Domínguez	30/12/2016	1
160	IMONCOLOGY	-	18/10/2016	1
090	HOSPITAL UNIV. PRÍNCIPE DE ASTURIAS	Dra. Fatima Navarro	20/04/2017	-
141	ONCOGRANADA	Dr. Joaquín Belón	27/09/2019	-
085	HOSPITAL UNIVERSITARIO DE BURGOS	Dr. Carlos García Gíron	14/11/2019	-
100	COSMPLEJO HOSP. UNIV.FERROL	Dr. F. Javier Afonso	09/03/2020	-
164	HOSPITAL DE GALDAKAO	Dra. Amaia Moreno	18/05/2020	-
050	HOSPITAL UNIV. CENTRAL DE ASTURIAS	Dra. Villanueva/Dr. Esteban	23/07/2020	-
124	HOSPITAL UNIV DE GUADALAJARA	Dr. Luis Chara	02/03/2022	-
109	IOB HOSPITAL QUIRÓN SALUD BARCELONA	Dra. Florencia García	22/06/2023	-
105	HOSPITAL DE GRANOLLERS	Dra. Sílvia Muñoz	En trámites	-
166	HOSPITAL DE SEGOVIA	Dra. Beatriz Esteban	En trámites	-

REGISTRO DE TUMORES TORÁCICOS: COMUNICACIONES Y PUBLICACIONES

COMUNICACIONES

- 2018:
 - Póster ESMO
 - Comunicación oral SEOM
- 2019:
 - 2 pósters IASLC
 - 3 pósters ESMO
 - 2 comunicaciones orales, 1 póster destacado, 2 pósters SEOM
- 2020:
 - 3 pósters ESMO
 - 6 pósters SEOM
 - 4 pósters IASLC
- 2021:
 - 1 comunicación oral IASLC
- 2022:
 - 2 pósters ELCC

PUBLICACIONES

- Transl Lung Cancer Res 2019;8(4):461-475
- Cancer Epidemiology 67 (2020) 101737
- ESMO Open 2020; 5:e001021.
doi:10.1136/esmooopen-2020-001021
- PLOS ONE |
<https://doi.org/10.1371/journal.pone.0251761> June 2, 2021
- Transl Lung Cancer Res 2021;10(10):3902-3911
- BMC Cancer (2021) 21:977
- BMC Cancer (2022) 22:732
- Gac Sanit. (2022);36(6):540-545.



Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study


- 1838 pacientes (01-JAN-2010 a 31-OCT-2019):
 - Estadio IIIA: 1082 (58.9%)
 - Estadio IIIB: 756 (41.1%)
 - No escamosos: 54%
 - Edad media: 66 años
 - Varones: 81.2%
 - Fumadores o exfumadores: 93.4%.
- Cirugía:
 - Estadio IIIA: 37%
 - Estadio IIIB: 11.1%
- QT-RT:
 - Estadio IIIA: 30.2%
 - Estadio IIIB: 37%
- OS:
 - No escamosos estadio IIIA: 37.4 meses
 - Escamosos estadio IIIA: 27.6 meses
 - No escamosos estadio IIIB: 25.7 meses
 - Escamosos estadio IIIB: 19.4 meses



RTT-ATLAS GECP 16/01

A Spanish nationwide biomarker NGS testing platform for Lung cancer

- 20 centros.
- 511 pacientes registrados.
- 480 muestras válidas (se prevén 1000).




*Datos de noviembre de 2023



RTT-ATLAS-RADÓN

Medición de radón en hogares de pacientes con cáncer de pulmón.

- 16 centros participantes (5 centros pendientes de inicio).
- 227 pacientes registrados (se prevén 500).



*Datos de noviembre de 2023



PLANET

Estudio observacional retrospectivo de los pacientes con NSCLC estadio IIIA resecables


- 17 centros participantes.
- Todavía no hay pacientes incluidos.



LUDICAS GECP 23/01

Características de la disfunción sexual en los pacientes con cáncer de pulmón

- 22 centros abiertos (pendiente la apertura de 2 centros).
- 286 pacientes incluidos (previstos 300-500).



*Datos de noviembre de 2023



VAC-CaP GECp 21/01

*Estudio observacional sobre la efectividad y la seguridad de la vacunación anti-SARS-COV2
en pacientes con cáncer de pulmón*

- 35 centros participantes.
- 1559 pacientes registrados.
- Pendiente informe final.
- Póster en ESMO 2022.
- Póster destacado en SEOM 2022.

1630P: VAC-CaP - Observational Study about the effectivity and safety of anti-SARS-CoV2 vaccination in patients with lung cancer (GECP 21/01)

Ernest Nadal¹, Teresa Moran², Delvys Rodríguez-Abreu³, Zara Vidales¹, M. Angeles Sala⁴, Mónica Antoñanzas⁵, Jorge García González⁶, Pilar Diz⁷, Mireia Martínez⁸, Guillermo López Vivanco⁹, Javier Baena¹⁰, Begoña Campos¹¹, José David Cumplido¹², Sara Cerezo¹³, Asunción Díaz¹⁴, María Guirado¹⁵, Xabier Mielgo¹⁶, Óscar Juan¹⁷, María Saigi², Mariano Provencio¹⁸

(1) Institut Català d'Oncologia, l'Hospitalet, Barcelona, Spain; (2) Institut Català d'Oncologia Badalona, Hospital Universitari Germans Trias i Pujol, B-ARGO, Barcelona, Spain; (3) Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain; (4) OSI Bilbao Basurto, Bilbao, Spain; (5) Hospital Clínico San Carlos, Madrid, Spain; (6) Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain; (7) Hospital Universitario de León, León, Spain; (8) Hospital Universitario Araba, Araba, Spain; (9) Hospital Universitario de Cruces, Barakaldo, Spain; (10) Hospital Universitario 12 de Octubre, Madrid, Spain; (11) Hospital Universitario Lucus Augusti, Lugo, Spain; (12) Hospital de Torrevieja, Alicante, Spain; (13) Hospital General La Mancha Centro, Ciudad Real, Spain; (14) Complejo Público Asistencial de Zamora, Zamora, Spain; (15) Hospital General Universitario de Elche, Elche, Spain; (16) Fundación Hospital Alcorcón, Madrid, Spain; (17) Hospital la Fe, Valencia Spain; (18) Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain



BACKGROUND

Patients with thoracic tumors have higher risk of severe COVID-19 and mortality due to COVID-19 than that reported for general population. During the first period of the pandemics, the mortality rate for patients with lung cancer was 33% and only 10% of patients who were candidates for intensive care or intubation were able to access this treatment (Whisenant *et al. J Thorac Oncol* 2022).

Several anti-SARS-CoV-2 vaccines were approved by the European Medicines Agency and had been administered to the general population, including patients with cancer. When this study was designed, limited data were available about the effectiveness and safety of anti-SARS-CoV-2 vaccines in cancer patients since these were excluded from the initial clinical trials.


We designed this retrospective observational study to collect data on the effectiveness and the safety of anti-SARS-CoV-2 vaccines in patients with lung cancer patients who are especially vulnerable to COVID-19 and have a higher risk of mortality than general population or that other patients with solid tumors.

OBJECTIVES and METHODS

- Primary endpoints:** to determine the safety and effectiveness of SARSCoV-2 vaccination in patients with lung cancer.
- Secondary endpoints:** a) to determine the frequency of COVID-19 and its severity in patients with lung cancer who received the SARS-CoV-2 vaccination; b) to determine the safety of the vaccine against SARS-CoV-2 and the toxicities associated with antineoplastic treatments in patients with lung cancer 3 months after receiving the vaccine.
- Key eligibility criteria:** Patients with lung cancer of any histology and stage who received the SARS-CoV-2 vaccination and signed the informed consent. Patients would be eligible whether they have suffered SARS-CoV2 infection as if they had not had COVID-19.
- The study was approved by the Ethical Committee and sponsored by the Spanish Lung Cancer Group (GECP).

Patients' characteristics (n= 794)	
Age, median (range)	66 (33.91)
Gender, n (%)	
Male	511 (64.4%)
Female	283 (35.6%)
Smoking status, n (%)	
Former smoker	420 (52.9%)
Current smoker	257 (32.4%)
Never smoker	115 (14.5%)
Unknown	2 (0.3%)
ECOG PS, n (%)	
0	278 (35%)
1	483 (60.8%)
2	32 (4.2%)
Histology, n (%)	
NSCLC	704 (88.7%)
SCLC	76 (9.6%)
Other	14 (1.7%)
Tumor stage, n (%)	
I-II	109 (13.7%)
III	161 (20.3%)
IV	449 (56.5%)
Unknown	75 (9.4%)
Cancer treatment, n (%)	
Yes	570 (71.8%)
No	224 (28.2%)
Type of treatment, n (%)	
Chemotherapy	364 (45.8%)
Immunotherapy	303 (38.2%)
Targeted therapy	115 (14.5%)
Radiotherapy	106 (13.4%)
Patients receiving vaccine	
1 st dose	794 (100%)
2 nd dose	789 (98%)
3 rd dose	593 (75%)


RESULTS



Most common adverse events after vaccination by CTCAE v.5.0

	All	1	2	3	4-5
Fever	66 (8.3%)	56	10	0	0
Pain in extremity	45 (5.7%)	45	0	0	0
Fatigue	30 (3.8%)	15	13	2	0
Pain	25 (3.1%)	24	1	0	0
Headache	15 (1.9%)	10	5	0	0
Myalgia	15 (1.9%)	7	7	1	0
Diarrhea	9 (1.1%)	7	1	1	0
Nausea	7 (0.9%)	4	3	0	0
Cough	4 (0.5%)	3	1	0	0
Dizziness	4 (0.5%)	3	1	0	0
Arthralgia	3 (0.4%)	2	0	1	0
Generalized muscle weakness	3 (0.4%)	2	1	0	0

Number of patients with COVID-19 infection



Characteristics of COVID-19 infection after vaccination (n=58)

COVID19 diagnosis	
Serology	2 (3%)
PCR	47 (81%)
Radiological	3 (5%)
Other	6 (10%)
COVID19 presentation	
Asymptomatic	18 (31%)
Paucisymptomatic	18 (31%)
Symptomatic	21 (36%)
Unknown	1 (2%)
Severity	
Hospitalization	10 (17%)
Intensive care unit	0 (0%)
Hospitalization	
Median number of days (range)	8 (1-32)
Treatments during hospitalization	
Oxygen therapy	10 (100%)
Ventilation	0 (0%)
Corticosteroids	7 (70%)
Antibiotics	7 (70%)
Anticoagulants	4 (40%)
Antivirals	3 (30%)
Antifungals	2 (20%)
Mortality due to COVID19	0 (0%)

CONCLUSIONS

Most patients received mRNA vaccines. Anti-SARS-CoV-2 vaccines are safe in patients with lung cancer and most vaccine-related adverse events are mild or moderate and similar to those observed in the general population. The rate of Covid-19 infection is low in this cohort of vaccinated patients with lung cancer and most COVID-19 cases were mild and managed without hospitalization. None of the patients required ventilation or was admitted in the intensive care unit neither died due to COVID-19 infection.



S-REAL

*Estudio de vida real español de pacientes con NSCLC estadio III irresecables
tratados con durvalumab y quimiorradioterapia*

- 40 centros participantes.
- 244 pacientes incluidos (previstos 250).
- Pendiente informe final.
- Póster destacado y comunicación oral en SEOM 2021.
- Manuscrito en preparación.



LORLAPULM GECP 21/04

Estudio retrospectivo observacional sobre la eficacia y seguridad de lorlatinib en NSCLC ALK+ y ROS1+ en pacientes tratados en el programa de uso compasivo en España.

- 32 centros participantes.
- 103 pacientes registrados (estimados 120).
- Pendiente informe final.
- Manuscrito en preparación.

15th MADRID
on **Lung** CONGRESS
CANCER
23&24
November 2023

#15CongressGeCP

Muchas Gracias